Vicore Pharma Holding AB (publ) (STO:VICO)

Market Cap	2.91B +71.3%
Revenue (ttm)	3.82M -96.5%
Net Income	-477.47M
EPS	-1.99
Shares Out	281.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,304
Average Volume	649,590
Open	10.48
Previous Close	10.58
Day's Range	10.28 - 10.50
52-Week Range	6.14 - 14.10
Beta	0.14
RSI	52.67
Earnings Date	May 6, 2026

About Vicore Pharma Holding AB

Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary arterial hypertension. It also developing Almee, an investigational medical device in clinical development that has completed Pha...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 36
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: VICO

Financial Performance

In 2025, Vicore Pharma Holding AB's revenue was 3.82 million, a decrease of -96.51% compared to the previous year's 109.35 million. Losses were -477.47 million, 183.1% more than in 2024.